Recommendations on Disease Management for Patients With Advanced Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer and Brain Metastases: ASCO Clinical Practice Guideline Update Summary
Year: 2018
Type: article
Abstract: The goal of this update is to provide oncologists, other health care practitioners, patients, and caregivers with recommendations regarding optimal management of patients with human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer and brain metastases. 1 ASCO first published two evidencebased clinical practice guidelines on optimal management of patients with HER2positive metastatic breast cancer in 2014.2,3 The goal of this 2018 guideline update is to provide oncologists and other clinicians with current recommendations regarding the treatment of patients with HER2-positive metastatic breast cancer and brain metastases.The current 2018 update assesses whether the 2014 recommendations remain valid.No additional evidence was identified that would warrant a change.A complete list of previous recommendations, the updated brain metastases HER2-Targeted Therapy for Patients With Advanced Breast Cancer guideline, 4 and additional information are available at www.asco.org/breast-cancer- guidelines.Patient information is available at www.cancer.net.
Source: Journal of Oncology Practice
DOI: 10.1200/jop.18.00291
Authors: Naren Ramakrishna, Sarah Temin, Nancy U. Lin
Language: English
Topic: HER2/EGFR in Cancer Research
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: bronze
OpenAlex ID: W2819850816